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a b s t r a c t
Introduction: Prophylaxis is the treatment of choice for patients with severe hemophilia. Low
adherence may limit the effectiveness of the prophylactic regimen, thereby compromising
outcomes.
Objective: The objective of this study was to validate the Brazilian version of the VERITAS-Pro
prophylaxis adherence scale, originally an American questionnaire that can be answered by
the individual responsible for prophylaxis as well as by an observer.
Methods: The scale has 24 questions divided into six subscales: Routine, Dosage, Plan,
Remember, Skip and Communicate. Participants were recruited at a blood center in south-
eastern Brazil for validation and reliability analyses. Validation measures included the
results obtained using analog visual scales of adherence, interval between medication dis-
pensed by the treatment center pharmacy and the percentage of recommended doses
administered and infusions registered in the patients’ logs.
Results: The study included 32 individuals responsible for prophylaxis and five observers.
The internal consistency was very good for the VERITAS-Pro total score, excellent for the
Remember, Skip and Communicate subscales, good for the Dosage subscale, and accept-
able for the Routine and Plan subscales. Twelve participants answered the questionnaire
on more than one occasion to evaluate reproducibility. The intraclass correlation coefficient
was excellent. Regarding convergent validity, the VERITAS-Pro scores were moderately cor-
related with the global adherence scale and with infusion log records, but showed a weak
correlation with pharmacy dispensation records.
∗ Corresponding author at: Fundação Centro De Hematologia E Hemoterapia De Minas Gerais (Hemominas), Barão de Cataguases S/N, Juiz
de Fora, MG, Brazil.
E-mail address: adriana.hemato@gmail.com (A.A. Ferreira).
https://doi.org/10.1016/j.bjhh.2017.09.002
2531-1379/© 2017 Published by Elsevier Editora Ltda. on behalf of Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular.
hematol transfus cell ther. 2 0 1 8;40(1):18–24 19
Conclusion: The Brazilian version of VERITAS-Pro is a valid and reliable instrument, enabling
the understanding of specific factors related to non-adherence and allowing targeted inter-
ventions for proper treatment.
© 2017 Published by Elsevier Editora Ltda. on behalf of Associação Brasileira de
Hematologia, Hemoterapia e Terapia Celular.
Introduction
Prophylaxis in hemophilia consists of regular infusions of clot-
ting factor VIII or IX concentrate for a period longer than
eight consecutive weeks in order to prevent bleeding.1,2 The
benefits of prophylaxis include decreased frequency of bleed-
ing episodes, decreased need for emergency room visits and
hospitalizations, prevention of arthropathy, increased phys-
ical activity and school attendance, and improved academic
performance.1,3–5 Prophylaxis reduces long-term morbidity,
thus improving quality of life.6,7 The World Health Organiza-
tion recommends prophylaxis as standard therapy for people
with severe hemophilia.2,8
Non-adherence to the prophylactic regimen may limit the
effectiveness of treatment with less prevention of bleeding.9
The lack of standardized methods to assess adherence to
hemophilia prophylaxis limits the understanding of factors
that facilitate or hinder the therapeutic program. Lack of
awareness of adherence as a determining factor in health out-
comes can lead to a waste of human and economic resources
as well as underutilization of available medications.10,11
VERITAS-Pro is a questionnaire created in the United
States, based on focus groups, to assess specific components
of adherence as well as global adherence to the proposed
prophylactic regimen.12 The objective of this study was to
describe the psychometric properties of the Brazilian version
of the VERITAS-Pro, demonstrating its usefulness as an instru-
ment for clinical practice and research.
Methods
Translation and adaptation
VERITAS-Pro, originally developed in English, was trans-
lated into Brazilian Portuguese according to international
translation and adaptation guidelines.13 Two independent
translations to Brazilian Portuguese were prepared by native
Brazilians. There were no relevant differences between the
translations. The two resulting versions were combined, cor-
rected by experts, and translated back into English by an
American translator without knowledge of the original docu-
ment. The Brazilian version has 24 questions divided into six
subscales: Time, Dose, Plan, Remember, Skip, and Communi-
cate, just as in the original questionnaire. The questions were
written in a way that made it possible for both the individual
responsible for the patient’s prophylaxis and an observer to
respond. The answers are presented as five-point Likert scales
ranging from ‘never’ to ‘always’. An ‘always’ response reflects
the best possible adherence for some items, and the worst for
others. For each item, a numerical classification was assigned
to the Likert scale, giving one point to the response represent-
ing the best adherence and five points to the worst adherence.
Possible scores of each subscale range from 4 to 20 points, and
the total score of the instrument, from 24 to 120 points, where
120 represents the worst adherence.
Participants
Participants were recruited at the Hemocentro Regional de Juiz
de Fora (HRJF) in southeastern Brazil. The individuals consid-
ered eligible were those responsible for the prophylaxis of
patients with hemophilia with a severe phenotype, A or B,
in a home infusion regimen for at least six months. Patients
in on-demand treatment, those not qualified to receive home
infusions, and those with inhibitors were excluded.
Participant recruitment and data collection
The study was approved beforehand by the Research Ethics
Committee of the Fundação Centro de Hematologia e Hemoterapia
de Minas Gerais – HEMOMINAS. The participants were asked
to respond to the questionnaire during their usual visits to
the blood center. All signed a free and informed consent form,
allowing access to their infusion logs, and received a guarantee
of confidentiality of any individual information. Parents gave
their consent to include data from patients under 18 years of
age, and adolescent patients (12–17 years old) gave their agree-
ment to participate. Sociodemographic and health data were
collected from the patients, as well as sociodemographic data
from those responsible for prophylaxis, in the case of under 18-
year-old and incapacitated patients. Participants answered a
questionnaire and a visual analog scale on global adherence to
prophylaxis. For the test–retest evaluation, participants were
asked to respond the questionnaire a second time on their
next visit to the blood center. Data collection occurred between
October 2015 and November 2016.
Other measures of adherence to prophylaxis
Analog scale of global adherence to prophylaxis
After completing the VERITAS-Pro, participants were
reminded of the details of the prescribed prophylaxis.
An analog scale with values ranging from zero (never follow
the prescription) to 10 (always follow the prescription) was
then presented and the participants were asked to rate their
adherence in the previous three months.
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Records of medications dispensed by the blood center
pharmacy
The number of doses dispensed was divided by the number
of doses required to comply with the prescribed prophylaxis
in the interval between dispensations. The analysis included
dispensations that provided sufficient factor for the previ-
ous twelve weeks of treatment. If the individuals responsible
returned later than the expected time for taking the required
doses, it became evident that prophylactic infusions were
skipped. However, if they returned at shorter than expected
intervals, as it was not possible to determine by this method
the reason for consumption greater than that prescribed, the
highest possible adherence was considered 100%.
Percentage of recommended doses administered
The percentage of doses administered on the correct days in
relation to the doses prescribed in the three months prior to
the application of the VERITAS-Pro was calculated from the
infusion logs filled out by those responsible for the patient’s
prophylaxis. When clearly documented, doses to treat bleed-
ing events were excluded. However, extra prophylactic doses
infused prior to medical and dental procedures, or unusual
physical activity, were included. Thus, the prophylaxis mea-
sured by this method could be greater than 100%, but for
analytical statistics reasons, 100% was considered the max-
imum possible adherence value.
Statistical analysis
Reliability and validity
Internal consistency was assessed using Cronbach’s alpha.
Since the subscales of the instrument contain only four items
each, the following considerations were used: 0.8 character-
ized excellent internal consistency; 0.7, very good; 0.6, good;
and >0.5, minimally acceptable.12 The intraclass correlation
coefficient (ICC) was used to evaluate the VERITAS-Pro scores
in the test–retest reliability analysis, which was considered
excellent when >0.75.13 The Spearman correlation test was
used to compare VERITAS-Pro results with the other adher-
ence measures.14 Statistical analysis was carried out using the
Statistical Package for the Social Sciences (SPSS) v.20 software.
Results
Participants
At the beginning of the study, in October 2015, there were
59 patients eligible for the prophylaxis regimen at the HRJF.
Twenty-three patients (39%) had opted to remain on episodic
treatment and one tested positive for an inhibitor (1.7%).
Of the 36 patients who adhered to the prophylactic treat-
ment, one was receiving the infusions at the blood center
and one presented severe clinical complications, requiring fre-
quent changes in the infusion scheme and, for these reasons,
they were excluded from the study. Thus, those responsible
for the prophylaxis of 34 patients and five observers were
recruited for the research, but two patients declined partic-
ipation. The 32 patients, whose prophylaxis adherence was
evaluated, were all males, 27 diagnosed with hemophilia A
Table 1 – Sociodemographic characteristics of patients
with hemophilia in a home prophylaxis regimen
between October 2015 and November 2016.
Sociodemographic characteristic
Age (years) – mean (range) 20.6 (3–60)









Schooling of over 18-year olds – n (%)
Higher education completed or in progress 9 (56.4)
High school diploma 1 (6.3)
Complete elementary education 1 (6.3)
Incomplete elementary education 4 (25)
No education at school 1 (6.3)
Occupation of those over 18 – n (%)
Student 7 (43.8)
Retired due to disability 6 (37.5)
Formal employee 2 (12.5)
Unemployed 1 (6.3)
Occupation of those under 18 – n (%)
Student 15 (93.8)
No occupation 1 (6.2)
(21 with factor VIII dosage <1%) and five with hemophilia B
(four with factor IX dosage <1%). The patients’ ages ranged
from three to 60 years (mean of 20.6 years, with a standard
deviation of 14.1). All the boys under the age of six were regu-
larly attending preschool. The patient was responsible for the
infusions in only 11 cases (34.3%). Tables 1 and 2 show the
sociodemographic and clinical characteristics of the patients,
respectively.
VERITAS-Pro scores
The total mean of the VERITAS-Pro was 35.51 (range: 24–70)
when the responses of those responsible for prophylaxis and
the observers were analyzed together. There was no statis-
tically significant difference when the scores were evaluated
separately (35.47 and 35.8, respectively; p-value = 0.914). There
was also no difference when the patients themselves were the
primary infusers (38.91) or others took on this responsibility
(33.81; p-value = 0.17). The averages of the subscales ranged
from 4.59 (Dose) to 7.3 (Time) (Table 3).
VERITAS-Pro reliability
Results showed a very good internal consistency for the
VERITAS-Pro total score; excellent for the Remember, Skip
and Communicate subscales; good for the Dose subscale;
and minimally acceptable for the Time and Plan subscales
(Table 4).
hematol transfus cell ther. 2 0 1 8;40(1):18–24 21
Table 2 – Clinical characteristics and therapeutic aspects
of hemophilia patients between October 2015 and
November 2016.
Clinical characteristic
Type of hemophilia – n (%)
A 27 (84.4)
B 5 (15.6)
Severity – n (%)
<1% Factor VIII or IX 25 (78.1)
1–2%b Factor VIII or IX 7 (21.9)
Family history of hemophilia – n (%)
Yes 18 (56.3)
No 14 (43.8)
Presence of target joints before prophylaxis started – n (%)
Yes 28 (87.5)
No 4 (12.5)
Clinically evident arthropathy – n (%)
Yes 18 (56.3)
No 14 (43.8)
Physiotherapy in the past three months – n (%)
Yes 5 (15.6)
No 27 (84.4)
Engage in regular physical activity – n (%)
Yes 20 (62.5)
No 12 (37.5)
Time in prophylaxis – median (range) 21.6 months (6.5–40.6)
Spontaneous hemarthrosis in the past three months – n (%)
None 20 (62.5)
1 or 2 9 (28.2)
3 or more 3 (9.4)




Other relative 1 (3.1)
Health professional 11 (34.4)
VERITAS-Pro reproducibility
Twelve participants (37.5%) agreed to answer the VERITAS-Pro
questionnaire on more than one occasion for test–retest relia-
bility analysis. The mean interval between the two responses
was 55.5 days (standard deviation of 11.9 days; range: 24–145
Table 4 – Internal consistency analysis of the Brazilian










Time 0.589 0.736 0.653
Dose 0.656 0.746 0.673
Plan 0.514 0.766 0.402
Remember 0.843 0.709 0.838
Skip 0.864 0.706 0.824
Communicate 0.826 0.731 0.635
Table 5 – Evaluation of reproducibility of the Brazilian
version of the VERITAS-Pro.




Total 33.58 32.75 0.933 <0.01
Time 6.83 6.42 0.895 <0.01
Dose 4.75 4.75 0.986 <0.01
Plan 5.42 5.17 0.536 0.11
Remember 5.58 5.75 0.929 <0.01
Skip 5.08 5.67 0.234 0.33
Communicate 5.92 5.00 0.835 <0.01
days). The ICC for the test–retest was excellent for the total
score (0.933; p-value <0.01), and for all subscales except for
the Plan and Skip domains (Table 5).
Adherence assessed by infusion logs
The infusion logs of 32 patients were evaluated regarding
the 12 weeks that preceded the application of the VERITAS-
Pro. In all cases it was not possible to identify prophylactic
infusions done outside the schedule of episodic infusions
for the treatment of hemorrhagic events. Those responsible
reported an average infusion rate of 72.17% of the prophylac-
tic doses prescribed in the period (range: 25–105.5%; standard
deviation: 25.8%). Half of those responsible for prophylaxis
reported infusion of 80% or more of the prescribed doses,
Table 3 – VERITAS-Pro total and subscale scores.
All participants Responsible Observers
Mean Range SD Mean Range SD Mean Range SD
Total 35.51 24–70 10.39 35.47 24–70 11.04 35.80 28–41 5.07
Time 7.30 4–14 2.47 7.19 4–14 2.50 8 6–11 2.34
Dose 4.59 4–12 1.67 4.59 4–12 1.73 4.60 4–7 1.34
Plan 5.51 4–13 2.06 5.47 4–13 2.17 5.80 4–7 1.30
Remember 5.57 4–14 2.55 5.56 4–14 2.67 5.60 4–8 1.81
Skip 6.08 4–16 2.77 6.06 4–16 2.87 6.20 4–9 2.28
Communicate 6.46 4–20 3.77 6.59 4–20 3.94 5.60 4–10 2.60
SD: standard deviation.
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which characterizes good adherence, when this is evaluated
dichotomously.7,10,15,16
Adherence measured by visual analog scale
The global adherence reported by 35 participants (31 responsi-
ble for infusions and four observers) through the analog scale
ranged from 6 to 10. Mean global adherence was 9.2 with a
standard deviation of 1.05 and a median of 10.
Adherence measured by the blood center pharmacy’s
dispensing of factor concentrate
The blood center pharmacy usually dispenses doses sufficient
for four weeks of prophylaxis on each visit of those responsible
for infusions. Thus, the individuals responsible are expected
to return with the used bottles at the end of this period and
replenish their household supply. The dispensing of doses suf-
ficient for prophylactic infusions in the 12 weeks prior to the
survey was analyzed, and the actual time until the return
of all used bottles was computed. Adherence was calculated
by dividing the number of doses dispensed by the number
of doses required to meet the prescription until the return,
revealing a mean adherence of 89.02% (standard deviation of
18.3, with a minimum of 45.9% and a maximum of 130%).
Concurrent validity of the VERITAS-Pro
Since better adherence is characterized by lower scores
on the VERITAS-Pro, higher scores on the visual analog
scale, and by higher adherence percentages based on phar-
macy dispensing and on infusion logs, negative correlations
indicate a stronger correspondence of VERITAS-Pro with
other adherence measures. Therefore, VERITAS-Pro scores
were moderately correlated with the global adherence scale
(r = −0.529; p-value = 0.002) and with the records in infusion
logs (r = −0.516; p-value = 0.003), but showed a weak cor-
relation with the pharmacy dispensing records (r = −0.32;
p-value = 0.074).
Discussion
Prophylaxis is considered the standard therapy for patients
with severe hemophilia17 as it is capable of preventing
arthropathy when begun early,18 and of reducing the num-
ber of bleeding episodes, and improving the quality of life
of individuals who already have irreversible joint damage.19
However, adherence to treatment is essential to achieve these
results.20,21
In Brazil, the prophylactic treatment regimens for
hemophilia were incorporated by the Brazilian National
Health System as of November 2011.22 The lack of a reliable
instrument to assess adherence to prophylaxis has been
one of the obstacles to research in this field since then.23 To
meet this need, the psychometric properties of the Brazilian
version of the VERITAS-Pro were evaluated, showing good
reliability and validity when applied to both those responsible
for prophylaxis and to observers of the treatment carried out.
The total score showed a very good internal consistency,
although lower than the original questionnaire (˛ = 0.737 ver-
sus ˛ = 0.92). In addition, the scores had a moderate correlation
with the visual scale of adherence and with the percentage of
administered infusions recorded in the patients’ logs. That is,
the Brazilian version of the VERITAS-Pro is a measure with
temporal stability and that relates with other measures of
adherence to prophylaxis. Almost all the subscales showed
good internal consistency, except for the Time (˛ = 0.589) and
Plan subscales (˛ = 0.514). Particular attention should be paid
to these subscales and items considering these subscales in
future analysis because their modification could improve the
quality of the scale. Unfortunately, a factorial analysis was not
possible due to the size of the sample.
The total score and all the subscales showed excellent
test–retest reliability, except for the Skip subscale (ICC = 0.234),
whose means increased significantly in the participant’s sec-
ond assessment. This increase, which translates as worsening
adherence in the Skip domain, was unexpected since individ-
uals tend to improve their behavior, albeit transiently, after
being evaluated for the first time.24
As in the original study, the Dose subscale exhibited the
lowest mean while the Time subscale presented the high-
est, indicating that participants reported better adherence in
administering the correct dose and worse in administering it
on prescribed days and times.12
In addition, as in the American work, the dispensing of
factor concentrates by the pharmacy was a less useful vali-
dation measure than the infusion logs and the visual scale
of adherence.12 This is explained by the fact that the dis-
pensing of medications includes variables that are not directly
related to patient adherence, such as the healthcare model of
the local health system. Cuesta-Barriuso et al. argue that free
treatment can weaken the patient’s commitment in following
through with the prescriptions, but not in the acquisition of
the medication.25 While the infusion logs represent an excel-
lent source of data for validation and are commonly used
to monitor infusions at home, they only provide quantitative
data.3,7,15,26
The superiority of the VERITAS-Pro over the global mea-
sures is due to its ability to recognize the multiple facets of
the adherence construct, represented by the subscales, and
to perceive different types of behavior. While the Time, Dose
and Skip subscales identify whether and when infusions were
administered, the Plan and Communicate domains reveal the
individual’s baseline behavior. This more comprehensive view
provided by the VERITAS-Pro assists in directing interventions
to improve adherence to prophylaxis.12
Another advantage of the Brazilian version of the VERITAS-
Pro was that it is easy to understand and quick to
complete, making it suitable for routine use in the clinical
practice.
It is believed that this is the first work in Brazil on adherence
to prophylaxis in hemophilia. Although small, the sample was
sufficient for the validation analyses of the Brazilian version of
the VERITAS-Pro. Unfortunately, subgroup analyses were lim-
ited by the low number of participants. Although differences in
adherence were not described according to the type or sever-
ity of hemophilia, or regarding the presence of infections such
as hepatitis C or human immunodeficiency virus,25 Miebach
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and Kalnins reported that adherence varies according to age
group and is lower among young adults.27 Studies with larger
populations are needed for these evaluations in the Brazilian
context.
Finally, it should be noted that although all the children
with severe hemophilia were in prophylaxis during this study,
the situation of the adults was quite different. The results
of this study showed that patients in the Brazilian sample
had higher adherence to treatment than those enrolled in the
study conducted by Duncan et al.,12 but a significant percent-
age chose to continue with episodic treatment, expressing the
lowest possible level of adherence to prophylaxis, yet these
patients were not considered by the VERITAS-Pro.
Conclusion
The Brazilian version of the VERITAS-Pro is a quantitative and
detailed instrument for assessing adherence to hemophilia
prophylaxis. Evidence from this study supports its validity
and reliability for use in the clinical and research contexts.
This validated scale can aid in the understanding of behav-
iors and in the identification of modifiable determinants
of non-adherence associated with unsatisfactory orthopedic
outcomes. The findings derived from the VERITAS-Pro can
facilitate the design of targeted interventions in these situa-
tions, but future studies are needed to confirm the relationship
between adherence, patient characteristics, and clinical out-
comes.
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